CytomX Therapeutics Inc. (CTMX) Trading Up 4.2%
Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) were up 4.2% on Wednesday . The company traded as high as $10.84 and last traded at $10.76, with a volume of 63,955 shares traded. The stock had previously closed at $10.33.
A number of analysts have weighed in on CTMX shares. Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $19.00.
The firm’s market capitalization is $387.94 million. The company’s 50 day moving average is $10.17 and its 200-day moving average is $12.42.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Friday, May 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.18. Equities analysts anticipate that CytomX Therapeutics Inc. will post ($1.61) earnings per share for the current fiscal year.
In other CytomX Therapeutics news, Director Timothy M. Shannon sold 48,427 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $10.07, for a total transaction of $487,659.89. Following the sale, the director now directly owns 134 shares of the company’s stock, valued at approximately $1,349.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ix L.P. Canaan sold 13,253 shares of the business’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $10.09, for a total transaction of $133,722.77. The disclosure for this sale can be found here.
A hedge fund recently bought a new stake in CytomX Therapeutics stock. Tekla Capital Management LLC bought a new stake in shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 328,059 shares of the company’s stock, valued at approximately $6,847,000. Tekla Capital Management LLC owned approximately 0.91% of CytomX Therapeutics at the end of the most recent reporting period.
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.